ACRS - Aclaris to slash 46% of workforce as it reprioritizes drug programs
2023-12-19 17:07:01 ET
More on Aclaris Therapeutics
- Stocks To Watch: Nvidia, Lowe's, Deere And Best Buy Line Up To Report
- Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer
- Aclaris Therapeutics announces patent license agreement with Sun Pharma for alopecia
- Aclaris plummets as mid-stage trial for arthritis therapy fails
- Seeking Alpha’s Quant Rating on Aclaris Therapeutics
For further details see:
Aclaris to slash 46% of workforce as it reprioritizes drug programs